Jun 21,2022

DarioHealth Announces New Contract with a National Employer

DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today announced a new contract to deliver its digital behavioral health solution for a leading provider of integrated technology solutions for financial professionals. The new account is expected to launch in the third quarter of 2022.

View Analyst & Ambassador Comments
Go to original news
Jun 23,2022

mPulse Mobile Announces Collaboration with Mount Sinai to Address Diabetes Risk Among Teenagers in East Harlem

mPulse Mobile, a leader in conversational AI and digital engagement solutions for the healthcare industry, announced their collaboration with the Mount Sinai Health System, New York City’s largest academic medical system, to deliver an innovative health program that addresses diabetes risk among teenagers in East Harlem.

COLLABORATION PARTNERSHIP

#product & service

View Analyst & Ambassador Comments
Go to original news
Jun 24,2022

Hygieia Advances its Global Business Development Activities with d-Nav® Program in Israel

Hygieia, a digital therapeutics company for insulin therapy, has successfully licensed its d-Nav insulin management technology to Movement Group, a provider of health and wellness programs to integrated health delivery networks in Israel. The agreement is part of an accelerated strategy to expand its d-Nav insulin titration technology globally. Movement is offering the program to patients within the largest integrated managed care and delivery networks in Israel.

COLLABORATION PARTNERSHIP

#product & service

View Analyst & Ambassador Comments
Go to original news
Jun 25,2022

DigiBete & JDRF Tech Talk & Peer Support Event

DigiBete announces its first joint event with JDRF – ‘Living with Type 1 Diabetes – Tech Talk & Peer Support’. The free type 1 diabetes information event will take place on Saturday 9 July – 10am – 1pm.

View Analyst & Ambassador Comments
Go to original news
Jun 28,2022

Point-of-Care Glucose Testing Market Report 2022-2030: Rising Prevalence of Diabetes and Demand for Short Turnaround Time Glucose POC Testing Driving Growth

The global point-of-care glucose testing market size is expected to reach USD 4.5 billion by 2030, growing at a CAGR of 4.1% over the forecast period.

View Analyst & Ambassador Comments
Go to original news
Jun 28,2022

Health2Sync, Sanofi partner to digitise insulin management in Japan

Taiwan-based digital health startup Health2Sync and French multinational pharmaceutical firm Sanofi have signed another partnership to bring digital solutions for insulin management to Japan. According to a press statement, both companies will jointly develop digitised features on insulin in Japan, including connected caps for insulin and titration alerts. 

 

COLLABORATION PARTNERSHIP

#r&d

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 29,2022

Dexcom focuses on early diabetes diagnosis as COVID links emerge

New evidence is showing that COVID-19 may increase a person’s risk of diabetes, but it could be years until we know for sure. In the meantime, Dexcom (Nasdaq:DXCM) is getting ready, VP of Global Clinical Initiatives Tomas Walker said. Walker discussed the San Diego-based diabetes device developer’s proactive approach to chronic COVID-19 conditions, technology that can help diagnose new cases, and the likelihood that particular devices and components will be in greater demand in the years ahead.

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 29,2022

DEXCOM AND ROCHE COLLABORATE FOR THE DISTRIBUTION OF THE CONTINUOUS REAL-TIME GLUCOSE MONITORING SYSTEM DEXCOM ONE IN ITALY

DexCom, Inc. ( NASDAQ: DXCM ), a world leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today that it has signed a definitive agreement with Roche Diabetes Care for the distribution in Italy of the Dexcom ONE real-time CGM system.

COLLABORATION PARTNERSHIP

#product & service

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 29,2022

ABBOTT HOSTS CONFERENCE CALL FOR SECOND-QUARTER EARNINGS

Abbott (NYSE: ABT) will announce its second-quarter 2022 financial results on Wednesday, July 20, 2022, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern), and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day.

View Analyst & Ambassador Comments
Go to original news
Jun 29,2022

Study Results Published in Diabetes Technology and Therapeutics Show Clinically Significant Improved Glycemic Control in People with Diabetes Using a Smart Blood Glucose Meter and Mobile App

LifeScan, a world leader in blood glucose monitoring, today announced that the peer-reviewed journal Diabetes Technology and Therapeutics (DTT) has published Real World Evidence of Improved Glycemic Control in People with Diabetes Using a Bluetooth® connected Blood Glucose Meter with Mobile Diabetes Management Application, describing results from a retrospective analysis of real-world data from more than 17,000 people with diabetes. A subset of these results was first presented at the 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in April.

CLINICAL STUDY

#bgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES